Navigation Links
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Date:4/8/2011

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME).  The companies are extending their development program for VEGF Trap-Eye in DME after promising results in the global Phase 2 DME program.

The first Phase 3 trial in DME, named VIVID-DME, is being led by Bayer HealthCare and has started in Australia.  The trial will also be conducted in Europe and Japan.  A second study led by Regeneron, named VISTA-DME, is expected to begin later in 2011 in the United States, Canada, and other countries.  

"Clinically significant DME is a leading cause of vision loss in adults under the age of 50 suffering from diabetes," said Dr. Kemal Malik, Head of Global Development and member of the Bayer HealthCare Executive Committee.  "After reporting positive results from our global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age-related macular degeneration (wet AMD), we are pleased to start a Phase 3 program with VEGF Trap-Eye in DME which may help to address this significant unmet medical need."

The Phase 3 program in DME expands the companies' global development collaboration for VEGF Trap-Eye.  The companies announced positive data for two Phase 3 studies in patients with wet AMD in November 2010 and for the first of two Phase 3 studies in patients with Central Retinal Vein Occlusion (CRVO) in December 2010.

About the Phase 3 DME Program

The VIVID-DME study (VEGF Trap-Eye In Vision Impairmen
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... FRANCISCO, Calif. , Sept. 2, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:9/2/2014)... , Switzerland , September 2, ... ISO 13485 accreditation, Sophia Genetics has become the first ... use of a Next Generation Sequencing (NGS) bioinformatic ... represents an important step in raising the standards ... brings Sophia Genetics, world-leading Data Driven Medicine platform ...
(Date:9/2/2014)... , Sept. 2, 2014  For over a decade SafeMinds ... link between vaccines and autism. But at least for one ... In a statement , William Thompson , Ph.D. ... linking the MMR vaccine to an increased risk of autism ... the same data suggests that African American males have a ...
Breaking Medicine Technology:Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3
... ... that a new market research report is available in ... A Worldwide Market Review , http://www.reportlinker.com/p0164283/Decubitus-Ulcer-Treatment-Products---A-Worldwide-Market-Review.html ... damage caused by constant pressure of the patient,s bodyweight. ...
... , KING OF PRUSSIA, Pa., Nov. 30 ... Phase I study of CPSI-2364, its orally active, small-molecule inhibitor ... Results of the safety and tolerability dose escalation study in ... clinical testing. , All 30 enrolled subjects completed ...
Cached Medicine Technology:Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 2Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 3Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 4Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 5Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 6Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... Niagara Falls, New York (PRWEB) September 02, 2014 ... scabies ?” This is the question that millions of ... challenge among health care providers, patients and their families ... lead to misdiagnosis due to its distinct similarities to ... atopic dermatitis, impetigo, bed bug bites, eczema, varicella and ...
(Date:9/2/2014)... September 02, 2014 QueenBeeTickets.com , home ... is now stocking James Taylor concert tickets for the singer’s ... U.S. cities from November 1 to the 19th. , James ... again on the 4th of the month. General onsales to ... are all set to obtain seats for one of his ...
(Date:9/2/2014)... September 02, 2014 ZAMST, a leader ... endorsement deal with professional baseball star Nolan Arenado ... best young baseball players, Arenado will be working with ... specific product category. , Arenado was selected by ... #59 overall. In 2013, Arenado was awarded the Gold ...
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
Breaking Medicine News(10 mins):Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:James Taylor Presale Tickets for 10 November Concerts On Sale Today From Trusted Provider QueenBeeTickets.com 2Health News:Gold Glove Baseball Star Nolan Arenado Signs With Zamst 2Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2
... Journal has just come out. In it,s 23rd year it helps new ... progress. It is both a keepsake, and a lifesaver in an emergency. ... inception. A diaper bag must. , ... Fountain Valley, CA (PRWEB) January ...
... Robert L. Peck discusses connections between the mind and body, hormone ... aware of the effects of hormones and how many of the ... ... Lebanon, CT (PRWEB) January 21, 2009 -- ,Controlling Your Hormones, ...
... CINCINNATI After identifying an apparent population of cancer ... herpes virus to block tumor formation in mice by ... 21 by PLoS (Public Library of Science) One ... Center adds to a growing body of evidence suggesting ...
... came into effect, granting children 12 years and older ... the right to access condoms. But current policies ... give out condomspolicies that two researchers, writing in this ... health of the country,s youth. , Juliana Han (Harvard ...
... , ... (PRWEB) January 20, 2009 -- It has come ... confusion as to the intentions of its iPhone application previously for ... to its attention-grabbing name, and the unfortunate media confusion and common ...
... health and exercise programs have positive outcomes despite having ... exercise they do outside of school, say Cochrane Researchers ... physical activity programs in schools. , The research shows ... and reduced the time spent watching television. Programs also ...
Cached Medicine News:Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 2Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 3Health News:Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life 2Health News:Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life 3Health News:Engineered virus targets and kills apparent cancer stem cells in neuroblastoma 2Health News:Engineered virus targets and kills apparent cancer stem cells in neuroblastoma 3Health News:South African policy on adolescents' rights to access condoms is causing confusion 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 3Health News:School-based physical activity: Has benefits even if it doesn't help lose weight 2
Enzyme Immunoassay of von Willebrand Factor Antigenby ELISA Method, 96 tests....
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests....
Enzyme Immunoassay of Platelet Factor 4 Antigen by ELISA Method, 96 tests....
HbA1c / HbCalibrator...
Medicine Products: